Haris Ali

Clinical trials

• Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

  Principal investigator · Recruiting · Phase 2

  City of Hope Medical Center

  2024–2030
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

  Principal investigator · Completed · Phase 2

  City of Hope Medical Center

  2020–2025
• Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

  Principal investigator · Completed · Phase 1

  City of Hope Medical Center

  2016–2023
• Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

  Principal investigator · Withdrawn · Phase 1

  City of Hope Medical Center

  2015